- Surgical Oncology
- Medical Oncology
- Radiation Oncology
- Oncology Nursing
- Other
- Body Limit: 420 words (1 original table/figure is allowed)
- Abstracts of Clinical Trials With Results to Be Presented
- Background/Significance: What was the problem, and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?
- Materials and Methods: What was the trial design? What was the sample? What instruments were used? How were data collected and analyzed?
- Results: What were the findings?
- Conclusions: What do the findings mean?
- Abstracts of Clinical Trials in Progress (ie, results not yet available)
- Background/Significance: What is the problem, and why is it important? What knowledge are you building on? What are the objectives of the study? What do you want to learn?
- Design and Methods: What is the trial design? What is the study population (including inclusion and exclusion criteria)? What is the statistical design? What are the study end points?
- Status: What is the current status of the trial (eg, enrollment status, participating study centers, anticipated completion date)?
- The title of the abstract should be brief and objectively describe the study. Do not use nonstandard abbreviations and commercial names (use generic names only). Use title case and capitalize all nouns, verbs, adverbs, and conjunctions of 4 letters or more. Do not capitalize a coordinating conjunction, an article, or a preposition of 3 or fewer letters, except when it is the first or last word in a title. Keep letters lowercase if the lowercase letters have a specific meaning, such as pH or mL. Do not put a period at the end of the title.
- Authors can be listed with institutional affiliations, cities, and countries only. Mailing addresses and academic degrees should not be mentioned in the author's list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract. Author list cannot modified once abstract is accepted.
- Presenting Author: The name, institution, telephone number, and email address of the Presenting Author are required. The Presenting Author will receive all future correspondence from PER®. The Presenting Author MUST be registered for the 43rd Annual Miami Breast Cancer Conference.
- Only 1 original data table or figure is permitted in the body of the abstract. (Does not go against your word count)
- Standard abbreviations in the body of the abstract may be used and must be spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lowercase. Commercial names may be included in the abstract text in parentheses, directly following the generic name at first use. For example, "generic (Commercial).” Do not use trademark symbols.
- Abstracts cannot be revised once submitted.
- The abstract must be submitted in English.
- Submissions can be edited until the deadline, but note that abstracts cannot be revised once submitted.
- Back again for 2026, first authors who are students, trainees, or early career oncologists may elect to be considered for the Early Career Distinguished Poster Presentation Award. Authors who would like to be considered for the award must indicate their interest during submission.
- The review committee will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed.
- Please note that we will only consider case series of ≥5 reports. We are not accepting case series of <5 patients or single-patient case reports.
- We are accepting Trial in Progress submissions and encore submissions.
- Notification of acceptance or regret will be delivered via email to the presenting author of each poster abstract in January 2026. Please note that the presenting author is required to be registered and present during the poster session.
- Prepare a visual abstract poster, which will be judged according to the following criteria:
- Visual quality
- Background clarity
- Appropriate methods
- Concise and accurate presentation of results
- Well-articulated conclusion/discussion
- Presenter knowledge and confidence
- Potential of research
- Accepted, original abstracts at the Miami Breast Cancer Conference (MBCC) will be published in a print supplement to the Oncology journal. All accepted abstracts will be published after the conference in an online-only supplement to Oncology, on the journal website. Previously presented (ie, encore) abstracts will not be published in Oncology; they will only be displayed in connection with the meeting (eg, online program).
- The MBCC organizers reserve the right not to publish abstracts that do not fit into any of the review categories, abstracts that inappropriately promote commercial interests, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the Program Committee.
- Waives any and all claims against Physicians' Education Resource®, LLC (PER®), sponsor of the 43rd Annual Miami Breast Cancer Conference, and any review arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
- Encore presentations (abstract and poster must indicate where originally presented)
- Late-breaking abstracts
- Literature reviews
- Research abstracts funded by for-profit organizations, including biotech and pharmaceutical
- Trials in progress:
- Trial must be open to accrual
- Abstracts/Posters for the “Trials in Progress” category cannot include endpoint data from the trial. If endpoint data are to be presented, please submit under the “Abstracts of Clinical Trials With Results to Be Presented” category.
- Selected abstracts will also be published in a print supplement to Oncology.
- Previously presented (encore) abstracts will not be published in Oncology; they will only be displayed in connection with the meeting (eg, online program).
What you need to know about abstracts:
Abstract Submission Deadline: January 5, 2026 5:00 PM ET
The program co-chairs of the 43rd Annual Miami Breast Cancer Conference® invite you to submit your abstracts to this year's conference, to be held March 5, 2026 to March 8, 2026, at the Fontainebleau Miami Beach in Miami Beach, Florida.
All abstract submissions must be made electronically through the Survey Monkey link provided.
For accepted abstracts, authors are required to create posters that utilize visual abstracts. More information on visual abstracts (including examples) is available here: Poster Creation Guidance.docx, and additional guidance will be communicated prior to the meeting.
Abstract Requirements
Your text abstract should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. The formal poster session is not designated for credit.
Share your research or best practices with your peers. Please classify your abstract into one of the following specialties:
Abstract Components
Abstract Format
Submission Process
Follow the Survey Monkey link to submit your abstract and contact information.
Abstract Publication
If accepted for presentation, abstracts and posters will be available for viewing online on the 2026 website during and after the conference; poster number, title, and author list will be included in the program handbook distributed to all attendees. The posters will be displayed on their assigned day during the poster walk. The presentation at the 43rd Annual Miami Breast Cancer Conference should reflect the submitted abstract, abstract title, authorship, and content. All presenters must register to attend the conference.
Author Consent and Waiver of Claims
Each abstract author agrees and certifies that he or she:
Answers to Frequently Asked Questions
1. PER will provide materials, including thumbtacks, to hang the poster.
2. Abstracts in the following categories will also be considered for presentation:
3. Abstracts are currently accepted only for a poster presentation, not oral presentation.
4. All accepted original abstracts at the Miami Breast Cancer Conference® will be available in the online program and will be published after the conference in an online-only supplement to Oncology, on the journal website.
5. Pharmaceutical industry authors are allowed to present abstracts.
6. There is no embargo on abstracts.
7. The room will become available to set up your poster 45 minutes before the start of the poster session.
Abstract Questions Please submit any questions pertaining to abstract submissions to onc-info@gotoper.com using the subject line "MBCC26 Abstract Question."